SLP:NASDAQSimulations Plus, Inc. Analysis
Data as of 2026-05-26 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Simulations Plus (SLP) trades at $15.28, comfortably above its 20‑day ($14.72) and 50‑day ($13.63) SMAs but still below the 200‑day SMA ($15.50), suggesting short‑term momentum with longer‑term caution. The RSI of 58 and a bullish MACD histogram (+0.013) reinforce a modest upside bias, while decreasing volume and a 30‑day volatility of 66% flag heightened price swings. Fundamentally, the stock appears undervalued: the DCF fair value of $17.78 implies a 55% upside, and its forward PE of 16.6 is well under the industry average of 27.4. Strong balance sheet metrics—$41.8 M cash, minimal debt ($0.5 M), and positive free cash flow ($17.2 M)—provide a cushion despite a current negative profit margin and ROE. The market sentiment is extremely bullish (Fear & Greed Index 91.2), but the high beta (1.27) and historic max drawdown of 65% underscore considerable risk.
Market Outlook
Short Term
< 1 yearKey Factors
- Price above short‑term SMAs with bullish MACD
- Decreasing volume and high 30‑day volatility
- Support level at $13.21 providing downside cushion
Medium Term
1–3 yearsKey Factors
- DCF‑derived upside of ~55% and price below fair value
- Forward PE discount to industry average
- Strong cash position and low debt enabling investment in growth
Long Term
> 3 yearsKey Factors
- Strategic positioning in AI‑driven drug discovery software
- Long‑term market tailwinds in health‑information services
- Robust balance sheet supporting sustainable R&D and expansion
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.